Skip to main content
Fig. 2 | Journal of Ovarian Research

Fig. 2

From: PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials

Fig. 2

Forest plot of aggregated data representing the hazard ratios of disease progression in recurrent OC and newly-diagnosed OC. OC-ovarian cancer, PARPi-poly ADP ribose polymerase inhibitor, BRCAm-breast cancer gene mutation, gBRCAm-germline breast cancer gene mutation, sBRCAm-somatic breast cancer gene mutation, BRCAw- breast cancer gene wild-type, CI-confidential interval

Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us